SymBio Pharmaceuticals Limited (4582.T) JPX
Currency In JPY
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In JPY
Address
Toranomon 30 Mori Building
Tokyo, 105-0001
Japan
Phone
81 3 5472 1125
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
108
First IPO Date
October 20, 2011
| Name | Title | Pay | Year Born |
| Fuminori Yoshida | Chief Executive Officer, President & Representative Director | 0 | 1949 |
| Minori Rosales | Corporate Officer, CMO of Oncology & Head of Japan Development Division | 0 | 1964 |
| Hiroyuki Horita | Corporate Officer | 0 | N/A |
| Edwin Rock | Corporate Officer, Corporate VP and Head of Global R&D Division | 0 | 1962 |
| Takeo Okuno | Corporate Officer & CFO | 0 | N/A |
| Masahiko Okuno | Corporate Officer | 0 | N/A |
| Yoshiharu Torikai | Corporate Officer | 0 | N/A |
| Tomonori Seta | Corporate Officer | 0 | N/A |
SymBio Pharmaceuticals Limited, established in 2005 and headquartered in Tokyo, Japan, is a pharmaceutical company focused on the research, development, production, and commercialization of medicinal products, primarily within the oncology and hematology fields for the Japanese market. The company's leading marketed anti-cancer drug is TREAKISYM (SyB L-0501), utilized for treating non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. TREAKISYM is also currently undergoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma. SymBio's development pipeline includes enhanced formulations of this drug: SyB L-1701, a ready-to-dilute version, and SyB L-1702, designed for rapid infusion. Beyond its cancer treatments, the company is advancing SyB L-1101, an intravenous formulation in Phase III trials for higher-risk myelodysplastic syndromes (HR-MDS), as well as SyB C-1101, an oral formulation in Phase II/III trials, combined with Azacitidine, also for HR-MDS. Additionally, SymBio is developing SyB V-1901, an antiviral medication targeting infectious diseases.